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ABSTRACT
Objective: The aim of the present study was to evaluate the efficacy of naringenin against antituberculosis drugs (ATDs) induced alteration in 
hematological parameters in rats.
Methods: Rats were administered with ATDs for 8 weeks (3 days/weeks) followed by naringenin at three different doses (10, 20, and 40 mg/kg) 
conjointly for 8 weeks (3 days/weeks) orally. After 8 weeks, animals were euthanized; blood was collected by retro-orbital sinus method for the 
analysis of hematological parameters.
Results: The results of this study show decreased in red blood cells, hemoglobin, mean corpuscular volume, mean corpuscular hemoglobin, mean 
corpuscular hemoglobin concentration, platelets, and eosinophils along with increase in the number of lymphocytes in ATDs induced rats. Treatment 
with naringenin encountered ATDs induced hematological parameter alteration which was evident by significant reversal in hematological indices 
toward control in dose-dependent manner.
Conclusion: The present study concluded that ATDs exposure caused adverse effects in various blood components and conjoint treatment of 
naringenin reduced hematological alterations toward control due to antioxidant activity.
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INTRODUCTION
Tuberculosis (TB) has been associated with significant morbidity and 
mortality and still remains a major global health problem. In 2015, the 
world had an estimated 10.4 million new TB cases in which over half of 
these were among men (5.9 million) and women constituted over a third 
(3.5 million), and 10% of cases were among children [1]. A multitherapy 
of the first-line antituberculosis drugs (ATDs) such as isoniazid, 
pyrazinamide, rifampicin, and ethambutol is used for the treatment of 
TB, for 2 months, followed by a combination of isoniazid/rifampicin for 
8 months [2]. These ATDs can cause various minor and major adverse 
reactions in the body include skin reactions, gastrointestinal disorder, 
neurological disorder, and vertigo [3]. ATDs also cause alterations in 
liver function tests and cause severe hepatotoxicity [4,5]. Less scientific 
information is available on ATDs induced alterations in hematological 
parameter. Thus, the present study was undertaken to investigate the 
therapeutic potential of naringenin against ATDs induced alterations in 
hematological parameter.
Natural remedies from medicinal plants and natural products 
are considered to be effective and safe alternative treatment for 
blood–borne diseases. Naringenin is a plant bioflavonoid mainly 
found in grapefruit, tomato, and citrus fruit and considered to have 
beneficial effects on human health [6]. Naringenin is a polyphenolic 
compound containing two benzene rings connected together with 
a heterocyclic pyrone ring [7]. Naringenin possesses a plethora of 
biological and pharmacological effects. Naringenin reported as an 
antioxidant, antimicrobial, anticancer, cholesterol-lowering agent [8], 
antidepressant [9], anti-inflammatory [10], hepatoprotective, and 
nephroprotective agents [11,12]. Thus, it was hypothesized that 
naringenin may be helpful in ameliorates ATDs induced alteration in 
blood parameters in rats.
MATERIALS AND METHODS
Animals and chemicals
Female albino rats of Wistar strain (150±10 g body weight) housed 
under standard husbandry condition (25±2°C temp., 60–70% relative 
humidity, 14 h light, and 10 h dark) were used in the study. The animals 
were fed on standard pelleted diet and drinking water ad libitum. 
Experiments were conducted in accordance with the guidelines 
set by the Committee for the Purpose of Control and Supervision 
of Experiments on Animals (CPCSEA), India. The study was carried 
out with the approval of the institutional animal ethics committee 
(994/Ere/Go/06/CPCSEA). The ATDs such as isoniazid, rifampicin, 
ethambutol, and pyrazinamide were generously obtained from the 
Government TB Hospital, Bilaspur (C.G.). Naringenin was purchased 
from Sigma-Aldrich Company.
Experimental protocols
Animals were divided into various groups of six animals each. Group I 
served as control and received vehicle only. Group II was administered 
with naringenin per se at the dose of 40 mg/kg orally. Groups III–VII 
were administered with pyrazinamide, ethambutol, isoniazid, and 
rifampicin at the doses of 210, 170, 85, and 65 mg/kg, respectively, 
for 8 weeks (3 alternative days in a week) and Group III served as 
experimental control. Animals of Groups IV, V, and VI were given 
naringenin at the doses of 10, 20, and 40 mg/kg, p.o, respectively, for 
8 weeks (3 alternative days in a week considering every next day of ATDs 
exposure). Group VII was treated with silymarin at dose of 50 mg/kg, 
p.o, same as naringenin as positive control. After 24 h of last treatment, 
blood was drawn from retro-orbital venous sinus by the conventional 
method [13]. Blood samples collected in ethylenediaminetetraacetic 
acid anticoagulant tubes (8.5%) were quickly returned by mixing with 
anticoagulant in the tube. Hematological parameters were analyzed: 
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indices for evaluating circulatory erythrocytes and used in the diagnosis 
of anemia and also serve as useful indices of the bone marrow capacity 
to produce RBCs as in mammals [18]. The MCH and MCHC were seen 
to be decreased in ATDs exposed groups might be due to decreased 
production of hemoglobin.
All the three doses of naringenin maintained RBC, hemoglobin, mean 
corpuscular volume, MCH, and MCHC near to control. Mean values 
depicted that naringenin doses of 10, 20, and 40 mg/kg therapy maintain 
hematological variables toward control, but 40 mg/kg dose of naringenin 
showed significantly (p≤0.01) increase in hemoglobin level. This increase 
may arise as a result of increase RBC count and possibly the mineral 
content of naringenin, especially iron content, an increase in iron supply is 
necessary to elevate the hemoglobin content. This suggests that naringenin 
may be useful in anemic conditions. Naringenin could modulate the heme 
metabolism and was noted for its biosynthetic ability under physiological 
and toxicological conditions, thereby minimizes the toxic effects in the 
blood. 20 and 40 mg/kg doses of naringenin show significant restoration 
in MCV (p≤0.01). Naringenin has ability to restore the MCV, MCH, and 
MCHC toward control and reduce the anemic condition in rats. The results 
were well compared with silymarin-treated positive control.
The therapeutic effect of naringenin on blood parameter such as 
platelets, eosinophils, and LYM against ATDs induced toxicity is well 
presented in Table 2. Blood platelets are implicated in blood clotting. 
ATDs administered rats showed low platelet concentration suggests 
that the process of clot formation resulting in excessive loss of blood in 
case of injury. Eosinophils are a type of white blood cell formed in the 
bone marrow. Prolonged use of ATDs caused alteration in eosinophil 
level [19,20]. Present findings showed significant (p≤0.01) decrease 
in the eosinophils count. The main role of LYM is to fight infections. 
Increased level of LYM showed that rats are more prone to have disease. 
The present observation indicates that ATDs groups have low immune 
system as they have elevated level of LYM in comparison to control 
groups (p≤0.01).
In the present study, naringenin therapies 10, 20, and 40 mg/kg 
doses show protective effect by normalizing the levels of treated 
Red blood cells (RBC), hemoglobin, mean corpuscular volume (MCV), 
mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin 
concentration (MCHC), platelets, eosinophils, and the number of 
lymphocytes (LYM). All hematological parameters were analyzed using 
the automated method with the automatic analyzer “Hematology 
Autoanalyzer Hema 2062+.”
Statistical analysis
The results were expressed as mean ± standard error of six animals used 
in each group. The differences between mean values were calculated 
by one-way analysis of variance (ANOVA) considered statistically 
significant at p≤0.05 level followed by student’s t-test [14].
RESULTS AND DISCUSSION
Hematological studies are useful in the diagnosis of the root cause of 
many diseases [15]. Hematological disorders indicate the abnormal 
condition in the profile of blood parameters, due to changes in 
metabolism. Long-term exposure to ATDs medication increases the 
risk of adverse drug reactions and toxicity. Isoniazid and rifampicin 
may directly cause hemolytic anemia [16]. The mean and standard 
deviation of hematological parameters such as RBC, hemoglobin, mean 
corpuscular volume, MCH, and MCHC of the blood of rats exposed 
to ATDs, and therapeutic effect of different doses of naringenin is 
shown in Table 1. Previous findings showed that administration of 
ATDs for 30 days altered the blood parameters results in decrease in 
RBC and hemoglobin in rats [17]. In the present study, rats treated 
with ATDs for 8 weeks showed decrease in RBC compared to control 
which, in turn, indicates anemic condition. Hemoglobin decreased 
significantly (p≤0.05) in the blood of ATDs induced rats relative to the 
control. However, reduction in hemoglobin can be probably due to the 
production of reactive oxygen species formed by the toxic metabolites 
of ATDs at the time of biotransformation of drugs. This results in the 
destruction of the RBC membrane and its function. MCV is a measure of 
the average volume of an RBC. A low MCV is an indication of microcytic 
anemia. The result suggests that the ATDs treated groups may have 
anemia as MCV is significantly lower (p≤0.01) as compared to control 
groups increase the anemic condition in rats. MCH and MCHC are major 
Table 1: Therapeutic effect of naringenin on blood parameter against ATDs induced toxicity
Groups RBC (106/mm3) Hb (g/dL) MCV (fl) MCH (pg) MCHC (g/dL)
Control 7.26±0.41 15.2±0.91 50.7±3.93 19.7±1.68 41.3±3.31
Naringenin per se 7.16±0.44 15.3±0.90 51.9±4.05 19.9±1.72 42.1±3.33
ATD 6.35±0.43 12.1±0.69ψ 33.1±2.70ф 16.5±1.02 33.6±2.88
ATD+Nar 10 6.69±0.47 12.8±0.94 42.2±3.96 18.1±1.82 38.8±2.43
ATD+Nar 20 6.82±0.39 13.7±0.84 47.6±3.75∗∗ 18.4±1.88 39.0±2.31
ATD+Nar 40 7.26±0.41 14.9±0.84∗ 48.8±3.81∗∗ 18.7±1.75 40.1±3.26
ATD+Sily 50 7.16±0.44 14.8±0.96∗ 50.9±4.01∗∗ 19.2±1.71 40.9±3.28
ANOVA 0.78 2.53§ 3.81§ 0.56 1.06
Data are mean±SE of n=6; ψATD versus control at p≤0.05, фATD versus control at p≤0.01, ∗ATD+Therapy versus ATD at p≤0.05, ∗∗ATD+Therapy versus ATD at p≤0.01, 
§Significant at 5% for ANOVA: Analysis of variance. RBC: Red blood cells, Hb: Hemoglobin, HCT: Hematocrit, MCV: Mean corpuscular volume, MCH: Mean corpuscular 
hemoglobin, MCHC: Mean corpuscular hemoglobin concentration, ATDs: Antituberculosis drugs, Nar 10: Naringenin 10 mg/kg, Nar 20: Naringenin 20 mg/kg, 
Nar 40: Naringenin 40 mg/kg, Sily 50: Silymarin 50 mg/kg, SE: Standard error
Table 2: Therapeutic effect of naringenin on blood parameter against ATDs induced toxicity
Groups Platelets (106/mm3) Eosinophils (106/mm3) LYM (103/mm3)
Control 850±71.7 4.4±0.32 72.5±4.33
Naringenin per se 803±78.1 4.5±0.31 73.2±4.19
ATD 695±56.4 1.2±0.07ф 92.0±5.12ψ
ATD+Nar 10 711±62.0 3.5±0.29∗∗ 90.0±4.96
ATD+Nar 20 734±59.7 3.5±0.29∗∗ 88.2±5.28
ATD+Nar 40 794±60.7 4.2±0.34∗∗ 84.0±4.81
ATD+Sily 50 825±60.3 4.3±0.33∗∗ 80.6±4.10
ANOVA 1.02 18.7§ 3.34§
Data are mean±SE of n=6; ψATD versus control at p≤0.05,фATD versus control at p≤0.01, ∗ATD+Therapy versus ATD at p≤0.05, ∗∗ATD+Therapy versus ATD at p≤0.01, 
§Significant at 5% for ANOVA: Analysis of variance. RDW: Red cell distribution width, LYM: Lymphocytes; ATDs: Antituberculosis drugs, Nar 10: Naringenin 10 mg/kg, 
Nar 20: Naringenin 20 mg/kg, Nar 40: Naringenin 40 mg/kg, Sily 50: Silymarin 50 mg/kg, SE: Standard error
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blood parameters. Naringenin capable to increase the platelet count 
as previously reported that they have wound healing properties [21]. 
Naringenin significantly (p≤0.01) maintained eosinophil level near 
control in dose-dependent manner. Treatment of naringenin also 
decreases LYM and improved body’s defense mechanism. No adverse 
effect was found in the blood parameters after per se treatment of 
naringenin. Naringenin showed dose-dependent recovery, especially 
40 mg/kg significantly elevate the RBC, hemoglobin, mean corpuscular 
volume, MCH, MCHC, platelets, and eosinophils along with decrease in 
the number of LYM to normalcy indicating capability of naringenin to 
scavenge free radicals caused by reactive metabolites of ATDs.
CONCLUSION
Administration of ATDs for 8 weeks caused changes in hematological 
parameters in rats. It can be concluded that naringenin has potential to 
reverse ATDs induced blood parameters alterations thus can be used as 
an excellent protective agent during ATDs regimen.
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